In Ewing tumor, the (11;22) chromosomal translocation produces a chimeric molecule composed of the aminoterminal domain of EWS fused to the carboxyl-terminal DNA-binding domain of FLI-1. Previously, we have identi®ed a novel protein TAF II 68, which is highly similar to EWS and another closely related protein TLS (also called FUS). We demonstrate that the N-terminus of TAF II 68 eciently stimulates transcription when fused to two dierent DNA binding domains and that overexpression of TAF II 68-FLI-1 chimeras in NIH3T3 cells leads to oncogenic transformation. We have also investigated the molecular mechanisms which could account for the transcriptional activation and the oncogenic transformation potential of the N-termini of TAF II 68 and EWS. Thus, we have tested whether the arti®cial recruitment of components of the preinitiation complex (PIC) or a histone acetyltransferase (HAT) could bypass the requirement for the activation domains of either EWS or TAF II 68. Recruitment of individual components of the transcription machinery or the GCN5 HAT is not sucient to promote activation from FLI-1 responsive genes either in transfection experiments or in oncogenic transformation assays. These results suggest that the TAF II 68 or EWS activation domains enhance a step after PIC formation in the transcriptional activation process.
Introduction
The genes encoding EWS and TLS are often the targets of chromosomal translocation in human sarcomas. EWS was originally discovered as being rearranged in Ewing sarcoma (Delattre et al., 1992) . It has since been found to be implicated in several dierent translocation events. These various somatic genetic rearrangements involving the gene encoding EWS result in the fusion of its N-terminal coding region to the C-terminal DNA binding domain (DBD) of one of several transcription factors including members of the ETS family like FLI-1, ERG, ETV1, E1AF and FEV or other transcription factors including ATF-1, WT1 and the orphan receptor TEC1 (for review see Rauscher, 1997; May and Denny, 1997) . In human myxoid liposarcoma, a chromosomal translocation event fuses the N-terminal domain of TLS to the transcription factor CHOP (Crozat et al., 1993; Rabbitts et al., 1993) and in acute myeloid leukemia to ERG (Panagopoulos et al., 1994) . EWS and TLS are homologous proteins which are involved in strikingly similar translocation events giving rise to the production of structurally similar oncoproteins. EWS-and TLS-derived fusion proteins contain the amino-terminus provided by one of the two homologous proteins fused to the DBD of one amongst several transcription factors. Cellular transformation by EWS-derived and TLS-derived fusion oncogenes is dependent on both the N-terminal sequence contributed by TLS or EWS and on the integrity of the DNA binding domain of the translocation partner (May et al., 1993a; Zinszner et al., 1994) . The N-terminal domains of the oncoproteins provided by TLS or EWS are potent transactivators when fused to heterologous DBDs (May et al., 1993b; Sanchez-Garcia and Rabbitts, 1994; Bailly et al., 1994; Zinszner et al., 1994; . It is thus believed that deregulation of target genes contacted by the DNA binding component of the oncogenic chimeras is a common mechanism involved in the transformation process (Brown et al., 1995; Braun et al., 1995; Bailly et al., 1994; Karnieli et al., 1996; Fujimura et al., 1996; Zinszner et al., 1994) .
We have previously identi®ed a novel protein, TAF II 68 which shares extensive sequence similarity with the human sarcoma-associated proteins EWS and TLS (also known as FUS) (Bertolotti et al., 1996) . Like EWS and TLS, hTAF II 68 contains a consensus RNA binding domain (RNP-CS) which allows it to bind not only RNA, but also single stranded (ss) DNA (Bertolotti et al., 1996) . The three closely related human proteins have a particularly conserved RNAbinding motif that deviates from the organization of such domains commonly found in other RNA-binding proteins. The most striking particularity of the RNP-CS motifs of hTAF II 68, EWS, and TLS is the presence of an unusually long predicted loop immediately after the ®rst a helix (Nagai et al., 1990; Burd and Dreyfuss, 1994; Bertolotti et al., 1996) . Thus, hTAF II 68, EWS, and TLS all belong to a new subfamily of RNP-CS containing proteins that we have called the TET family (Bertolotti et al., 1996) . The common structural features which are limited to the TET family members suggest that they bind RNA and/or ssDNA in a unique way. TAF II 68 was identi®ed as a subunit of a speci®c population of the TFIID complex. TFIID is a multiprotein complex composed of the TATA binding protein (TBP) and TBP associated factors (TAF II s) and its binding to the promoter is the ®rst step of preinitiation complex assembly on protein coding genes (Roeder, 1996; Bell and Tora, 1999) . We have shown that dierent TFIID complexes exist in human HeLa cells and that they exhibit functional speci®city (Brou et al., 1993a,b; Jacq et al., 1994; Bell and Tora, 1999) . TAF II 68 is also associated with another multiprotein complex, the human RNA polymerase II (Pol II) and is able to enter into the preinitiation complex together with Pol II (Bertolotti et al., 1996) . This suggests TAF II 68 may be a bridging factor between transcription initiation and elongation. We have recently demonstrated that the structural resemblance of the TET family members can be extended to certain functional similarities. Indeed, TLS, EWS are also associated with TFIID, but interestingly, they are each present in a distinct TFIID population (Bertolotti et al., 1996 (Bertolotti et al., , 1998 . Moreover, like TAF II 68, EWS is also associated with Pol II (Bertolotti et al., 1998) . Together, these results suggests that the TET proteins family members share common functional properties but they exhibit subtle dierences. Since the TET family members are associated with two complexes involved in transcription of proteins coding genes, TFIID and RNA Pol II, they may participate in transcriptional regulation of class II genes. This hypothesis is reinforced by the observation that a Drosophila protein, homologous to the TET family members [termed Cabeza (Stolow and Haynes, 1995) or SARFH (Immanuel et al., 1995) ], was found to be associated with the majority of active transcription units in preparations of polythene chromosomes from salivary gland nuclei (Immanuel et al., 1995) .
TLS seems to be involved in regulation of more than one aspect of gene expression. TLS is identical to hnRNP-P2, a subunit of a complex involved in maturation of RNA precursors (Calvio et al., 1995) and like many hnRNP proteins, TLS can shuttle between the nucleus and the cytoplasm (Zinszner et al., 1994 (Zinszner et al., , 1997 . Thus, TLS could enter into the preinitiation complex (PIC) with TFIID, later associate with the elongating RNA polymerase II and play a role in mRNA processing. These properties are similar to those of the cleavage-polyadenylation speci®city factor (CPSF), which was recently shown to be brought to the PIC by TFIID (Dantonel et al., 1997) . Moreover, CPSF is also associated with the CTD of RNA Pol II (McCracken et al., 1997; Hirose and Manley, 1998 ) a feature shared with certain splicing factors (Mortillaro et al., 1996; Yuryev et al., 1996) . Consistent with these observations, TLS, and probably also TAF II 68 and EWS could play a role in coupling transcription and mRNA processing.
Since TAF II 68, EWS and TLS share many common characteristics, we hypothesized that the N-terminus of hTAF II 68 could also have transactivation and transforming properties. To address this question we have analysed the ability of hTAF II 68 N-terminus to activate transcription, as well as its ability to transform NIH3T3 cells when fused to the DBD of FLI-1.
During the transcriptional activation process, activators are thought to stimulate and/or facilitate the formation of PIC. Numerous biochemical analyses have suggested that activation domains can directly or indirectly contact components of the basal transcription machinery (Tjian and Maniatis, 1994; Ranish and Hahn, 1996) . As a consequence, these interactions recruit, stabilize and also induce conformational changes of the PIC (Goodrich et al., 1996; Roberts and Green, 1994; Barberis and Gaudreau, 1998) . Transcriptional regulation by activators also involves modi®cation of chromatin by recruiting chromatin remodelling complexes to promoters to de-compact the chromatin structure around the genes which will be transcribed (Kuo and Allis, 1998; Workman and Kingston, 1998) . In agreement with these results, it has been shown that activation domains can interact with histone acetyl transferases (HATs) (Workman and Kingston, 1998) . As a consequence, these interactions open the chromatin structure around the promoter and therefore, facilitate the recruitment of the preinitiation complex to the initiation site (Roberts and Green, 1994; Chi and Carey, 1996; Wang et al., 1992; Chrivia et al., 1993; Workman and Kingston, 1998) . Recently, it was shown that arti®cial recruitment of one of various components of the basal transcription machinery or HAT is sucient to stimulate transcription (Chatterjee and Struhl, 1995; Xiao et al., 1995; Klages and Strubin, 1995; Apone et al., 1996; Barberis et al., 1995; Gonzalez-Couto et al., 1997; Himmelfarb et al., 1990; Farrell et al., 1996; Xiao et al., 1997; MartinezBalbas et al., 1998; Barberis and Gaudreau, 1998) . These ®ndings suggest that overcoming the rate limiting step of preinitiation complex assembly can be sucient to promote gene activation. Here we tested whether the arti®cial recruitment of components of the transcription machinery or a HAT could bypass the requirement for the activation domains of either EWS or TAF II 68 on FLI-1 responsive promoters.
Results
The amino-terminus of TAF II 68 contains a transactivation domain
To analyse whether the amino-terminus of TAF II 68 contains a transactivation domain, we constructed two chimeric proteins: GAL4-TAF II 68DC198 and GAL4-TAF II 68DC328 (Figure 1a ). GAL4-TAF II 68DC198 is composed of the N-terminal 198 amino acids of TAF II 68 fused to the heterologous DBD of the yeast GAL4 activator, and the longer chimera (GAL4-TAF II 68DC328) contains the N-terminal 328 amino acids of TAF II 68, including the ®rst RGG repeat containing region and the RNP-CS motif, fused to the GAL4 DBD ( Figure 1a) . As a positive control, we also constructed a GAL4-EWS chimera (Figure 1a ). These constructs were transfected into HeLa cells together with the 17M2-G.CAT reporter gene (Webster et al., 1988b) containing two GAL4 binding sites upstream of the rabbit b-globin promoter fused to the CAT reporter gene (schematized in Figure 2a ). As expected transcription of the CAT gene was eciently stimulated by GAL4-EWS when compared to the activation obtained by the transfection of the empty vector ( Figure 2a , compare 12 to lane 1). GAL4-TAF II 68DC198 activated expression of the CAT reporter gene in a similar dose-dependant manner as GAL4-EWS however, with a lower magnitude ( Figure  2a , compare lanes 16 ± 22 to lanes 9 ± 15). In contrast, surprisingly the longer TAF II 68 chimera (GAL4-TAF II 68DC328) did not activate transcription, probably due to the presence of the RNP-CS motif in the this fusion protein, which may mask the activation domain (Bertolotti et al., 1998) . Overexpression of the negative control GAL4 DBD does not stimulate transcription of the same reporter gene. Moreover, a maximum stimulation was obtained by transfecting 100 ng of each expression vector which gave rise to approximately 50-fold activation by GAL4-EWS (Figure 2a , lane 12) and 24-fold GAL4-TAF II 68DC198 (Figure 2a , lane 19). When more than 100 ng of the dierent expression vectors have been transfected, transcriptional activation decreased (Figure 2a, lanes 13 ± 15 and 20 ± 22) . This eect can be interpreted as transcriptional interference or squelching that could re¯ect the titration of a limiting factor(s) required in the transactivation process by an activator (Gill and Ptashne, 1988; Tasset et al., 1990) . Thus, the N-terminal 198 amino acids region of TAF II 68 contains a transcriptional activation domain, similarly to the homologous domains of EWS and TLS.
EWS-FLI-1 has been shown to activate transcription from various reporter genes under the control of dierent ETS-responsive promoters (Bailly et al., 1994; Ohno et al., 1993) . We next tested whether the amino-terminus of TAF II 68 can also activate transcription from ETS responsive promoters. Therefore, we generated two dierent TAF II 68-FLI-1 fusion proteins. By alignment of TAF II 68 and EWS proteins and their genomic sequences (data not shown), we found that the ®rst 159 amino acids of TAF II 68 correspond to the domain of EWS present in the type II EWS-FLI-1 fusion proteins (Delattre et al., 1992) . Therefore, we generated the TAF II 68DC159-FLI-1 fusion ( Figure 1 ). As the ®rst 198 amino acids of TAF II 68 were found to activate transcription eciently when fused to GAL4 on the 17M2-G.CAT reporter gene we generated the TAF II 68DC198-FLI-1 chimera as well (Figure 1 ). In contrast, as the the longer TAF II 68 chimera did not activate transcription when fused to the GAL4 DBD, we did not further analyse this chimera. ETS proteins have been shown to activate transcription of the HTLV-1 long terminal repeat (LTR) through binding to two ETS binding sites (EBS) contained in this promoter region (Gegonne et al., 1993; Bosselut et al., 1990) . Moreover, it has been shown that EWS-FLI-1 can activate transcription from a reporter gene containing two tandem copies of the ETS responsive element of the HTLV-1 LTR (Bailly et al., 1994) . Similarly, transcription from a reporter gene composed of the HTLV-1 LTR (schematized in Figure 2b ) fused to the CAT gene (Brady et al., 1987) Together, these results demonstrate that TAF II 68-FLI-1 fusion proteins are functionally similar to EWS-FLI-1 in their ability to stimulate the expression of an ETS responsive gene. Moreover, similarly to EWS-FLI-1, TAF II 68-FLI-1 fusion proteins are more potent transcriptional activators than FLI-1. Since the amino-terminus of TAF II 68, without the RGG repeats and the RNP-CS motif, activates transcription when fused to two dierent DBDs [independently of its position (Figures 1 and 2 )], we conclude that this domain contains an autonomous transcription activation domain.
TAF II 68-FLI-1 chimeras transform NIH3T3 cells EWS-FLI-1 is thought to exert its oncogenic activity by deregulating expression of FLI-1 target genes (Brown et al., 1995; Braun et al., 1995; Bailly et al., 1994; Karnieli et al., 1996; Fujimura et al., 1996; Zinszner et al., 1994) . Moreover, it has previously been shown that strong activation domains, like the acidic activation domain of VP16, when fused to FLI-1 can transform NIH3T3 cells . Thus, a strong correlation exists between the strength of an activation domain and its oncogenic Note that all fusion proteins migrate much slower than their predicted molecular weight suggesting that they are the targets of posttranslational modi®cations.
When plated in soft agar, both TAF II 68DC159-FLI-1 and TAF II 68DC198-FLI-1 expressing cells were able to form macroscopic colonies ( Figure 4) . As previously reported, EWS-FLI-1 transforms NIH3T3 cells whereas FLI-1 does not (May et al., 1993b) , nor does the empty vector (Figure 4) The two dierent TAF II 68DC159-FLI-1 and TAF II 68DC198-FLI-1 fusion proteins transform NIH3T3 cells with about the same eciency (135 and 128 colonies formed respectively) but are about three times less ecient than EWS-FLI-1 (430 colonies). These (7) together with 1 mg of the 17 M2-G-CAT reporter plasmid schematized at the top of the ®gure, containing two GAL4 binding sites (17M2). The phosphoimager quanti®cation of the CAT assays are presented as histograms in term of fold stimulation. (b) TAF II 68-FLI-1 is a transcriptional activator on an EBS-containing promoter. HeLa cells were transfected with 20 or 100 ng of the indicated expression vectors together with 1 mg of the 10-1 reporter plasmid (Brady et al., 1987) , containing the HTLV-1 LTR, schematized at the top of the ®gure. Hatched boxes represent the two ETS binding sites (EBS) of the HTLV-1 promoter. Histogram depicting the quantitation of CAT activity is presented. In (a) and (b) each histogram represents the mean of at least three independent transfections after normalization for the internal control luciferase activity results demonstrate that TAF II 68-FLI-1 chimeras can induce oncogenic transformation, being however less potent oncoproteins than EWS-FLI-1. In conclusion, the amino-terminus of TAF II 68 displays not only transactivation but also transformation properties.
The recruitment of various components of the preinitiation complex or the GCN5 HAT to ETS-responsive promoters is not sucient to activate transcription nor to promote cellular transformation Since transcriptional stimulation of the FLI-1 target genes by EWS-FLI-1 or TAF II 68-FLI-1 leads to oncogenic transformation, we next investigated the molecular mechanism of activation of these genes in vivo. We have previously shown that both EWS and TAF II 68 are associated with TFIID and the RNA Pol II complexes (Bertolotti et al., 1996 (Bertolotti et al., , 1998 . Moreover, the amino-termini of either EWS or TAF II 68 directly interact with certain subunits of the TFIID and the RNA Pol II complexes (Bertolotti et al., 1998) . It has been shown that arti®cial recruitment of components of the PIC or a HAT to promoters could lead to transcriptional activation (see Introduction). To analyse whether the transcriptional activation and transforming properties of EWS-FLI-1 or TAF II 68-FLI-1 could be achieved by the facilitation or the stimulation of PIC formation, we investigated whether activation of ETS responsive genes and transformation could be obtained by arti®cial recruitment of dierent PIC components or a HAT. For this purpose, we generated fusion proteins composed of either one of the TFIID subunits (TBP and TAF II 28), one of the Pol II subunits (RPB3 and RPB7) or the GCN5 HAT fused to the FLI-1 C-terminal domain (Figure 1b) . The ®rst 96 amino acids of TBP are composed of 38 glutamines, and this glutamine rich content is characteristic of some transcription activation domains (Mitchell and Tjian, 1989; Seipel et al., 1993) . When this region of TBP is fused to a heterologous DBD it is able to activate transcription (Seipel et al., 1993) . Therefore, in our TBP-FLI-1 fusion protein this glutamine rich N-terminal end of TBP has been removed (Figure 1b) . The full length coding sequences of hTAF II 28, hRPB3 and hRPB7 where also fused to FLI-1 C-terminal domain (Figure 1b) . To create the GCN5-FLI-1 chimera, the GCN5 cDNA which encodes the short form of human GCN5 protein (also called hGCN5-S) with a similar size to yeast GCN5 (Candau et al., 1996; Smith et al., 1998; Xu et al., 1998) , were fused to FLI-1 C-terminal domain (Figure 1b) . The dierent TAF II -FLI-1 and TBP-FLI-1 chimeras were named TFIID-FLI-1 fusions, the chimeras containing the dierent Pol II subunits were named`Pol II-FLI-1' fusions and the chimera with the GCN5 was named`HAT-FLI-1'.
We tested whether the TFIID-, Pol II-and HAT-FLI-1 chimeras could activate transcription in mammalian cells similarly to EWS-FLI-1 or TAF II 68-FLI-1. When the various TFIID-FLI-1, Pol II-FLI-1 or GCN5-FLI-1 expression vectors were transfected in HeLa cells together with a reporter plasmid responsive to EWS-FLI-1, none of them activated transcription eciently when compared to EWS-FLI-1 ( Figure 5 ). However, similarly to the EWS-and TAF II 68-FLI-1 chimeras (Figures 2b and  5 ) an inhibition of transcription was observed from the HTLV-1 LTR when more than 20 ng of expression vector was transfected for TFIID-FLI-1, Pol II-FLI-1 and the GCN5-FLI-1 chimeras ( Figure  5 ; and data not shown) probably by competing for the binding to the ETS-binding sites (EBSs) with the endogenous ETS proteins. These results together with Western blot analyses (Figure 3 and data not shown) indicate that the dierent chimeras are expressed and that they are able to bind to their binding sites on the promoter tested. Importantly, when more than 1 mg of TBP-FLI-1 (or GAL-TBP) expression vector was transfected into HeLa cells, the luciferase expression that was used to normalize transfection eciencies was always strongly inhibited (data not shown), indicating that high fusion protein concentration in the cells impair transcription in general and thus cannot be used in our transfection system. In conclusion, the fusion of a core subunit of the preinitiation complex or the GCN5 HAT to the FLI-1 DBD is not sucient to mediate transcriptional activation of the tested ETS responsive gene.
To test the dierent TFIID-, Pol II-or GCN5-FLI-1 chimeras on natural endogenous promoters, the various fusion proteins were retrovirally transduced into NIH3T3 cells. Nuclear extracts were prepared from the dierent cell lines and protein expression was analysed by Western blot using an anti-FLI-1 antibody. All fusions were expressed and localized in the nucleus (Figure 3 , and data not shown). Polyclonal cell populations were next analysed in soft agar assays in order to determine their oncogenic properties. The TFIID-, Pol II-or GCN5-FLI-1 fusion proteins were unable to promote the formation of colonies in soft agar even after more than 6 weeks of growth ( Figure  6 ). These results demonstrate that the TFIID or Pol II subunit derived fusion proteins and GCN5-FLI-1 chimera, which have no transactivation properties on the EWS-FLI-1 responsive gene tested, have no oncogenic properties when overexpressed in NIH3T3 cells. In conclusion, there is a good correlation between the transactivation potential and the oncogenic properties of the FLI-1 fusion proteins further suggesting that deregulation of FLI-1 target genes is a key mechanism of oncogenic transformation. The fact 
Discussion

TAF II 68 is a proto-oncogene
Here we show that the N-terminal domain of TAF II 68 has oncogenic properties when it is fused to the FLI-1 DBD since TAF II 68-FLI-1 chimeras lead to oncogenic EWS-FLI-1 is a more potent transcriptional activator than FLI-1, and in contrast to FLI-1, can transform NIH3T3 cells (May et al., 1993b) . TLS and EWS are the targets of various translocation events in human sarcoma. To date, eight translocation partners have been found for EWS and two for TLS which are strikingly common to TLS (see Introduction). In each case, the translocation event fuses the N-terminal domain of one of the two related proteins to the DBD of one of several transcription factors, removing the C-terminal RNA binding domain of the germline EWS or TLS protein. Like the other TET family members, we found that the N-terminus of TAF II 68 contains a transcriptional activation domain which can activate transcription when fused to two heterologous DBDs (Figure 2) . However, GAL-TAF II 68 fusions exhibit about a twofold weaker activation potential than GAL-EWS on a GAL4 responsive promoter. When fused to the FLI-1 Cterminal domain present in the oncogenic protein expressed in Ewing tumor, the N-terminal domain of TAF II 68 has similar transactivation properties as the N-terminal domain of EWS on a EWS-FLI-1 responsive reporter gene. Since the transformation by EWS-FLI-1 is thought to be a consequence of deregulation of FLI-1 target genes, and having shown that TAF II 68-FLI-1 is a more potent transactivator than FLI-1 (Figure 2b) , we tested the oncogenic properties of TAF II 68-FLI-1. NIH3T3 cells overexpressing the N-terminal 198 amino acids of TAF II 68-FLI-1 form colonies in soft agar similarly to cells expressing EWS-FLI-1 in contrast to FLI-1 (Figure 4) . However, TAF II 68-FLI-1 is about three times less oncogenic in this essay than EWS-FLI-1 even though the two proteins were expressed at approximately the same levels (Figure 3) . The dierences in the oncogenic eciency of the two fusion proteins can be correlated with the observation that GAL-TAF II 68 is about twofold less potent activator than GAL4-EWS (Figure 2a ). This difference is undetectable in the case of the TAF II 68-FLI-1 or EWS-FLI-1 fusion proteins on the ETS responsive reporter may be because the maximum stimulation observed is much lower than the one obtained with the GAL4 responsive reporter (Figure 2a,b) . Nevertheless, TAF II 68 N-terminus is a strong transactivation domain and thus, there is a good correlation between the transactivation eciency and the oncogenic capacity of TAF II 68. Our results further support the model in which the oncogenic transformation by EWS-FLI-1 in Ewing tumors is a direct consequence of its ability to stimulate eciently FLI-1 responsive genes. Consistent with these results, it has previously been shown that strong activation domains, like the acidic activation domain of VP16, when fused to FLI-1 can transform NIH3T3 cells . Thus, the strength of a transcriptional activation domain may determine its oncogenic transformation capacity in the context of a fusion transcription factor created by chromosomal translocations (see also below). Although the gene encoding TAF II 68 has not yet been implicated in human cancers, our results suggest that the TAF II 68 gene is a proto-oncogene and that the hTAF II 68 gene could potentially be involved in chromosomal rearrangement(s) in human tumors.
Arti®cial recruitment of components of the PIC or the GCN5 HAT does not substitute for transcriptional activation on ETS responsive genes
Having demonstrated that TAF II 68 N-terminus can activate transcription when fused to FLI-1 DBD and that the TAF II 68-FLI-1 chimeric proteins can transform NIH3T3 cells similarly to EWS-FLI-1 we investigated the molecular mechanism by which these activators stimulate transcription. We have previously shown that TAF II 68 and EWS N-termini can establish contacts with several TFIID and Pol II subunits (Bertolotti et al., 1998) . It has been proposed that a single interaction between a transcriptional activation domain and a component of the holoenzyme can be sucient to promote gene activation (for review see Barberis and Gaudreau, 1998) . To test whether the transcriptional stimulation by TAF II 68 or EWS Nterminal activation domains could be bypassed by arti®cial recruitment of the PIC or a HAT we generated several TFIID-, Pol II-or HAT-FLI-1 fusion proteins. None of these chimeras mediate transcriptional activation on the FLI-1 responsive HTLV-1 LTR reporter gene in HeLa cells (Figure 4) and from other natural FLI-1 responsive promoters in NIH3T3 cells (Figure 6 ). Recruitment of TFIID to the promoter is amongst the early events that leads to the assembly of an active PIC. On the FLI-1 responsive promoter, recruitment of TBP or dierent TAF II s by the FLI-1 DBD is not sucient to stimulate transcription. Note that in our study the same region of TBP was fused to the FLI-1 C-terminal domain as the one used by Xiao et al. (1997) to generate a GAL4-TBP fusion protein which is able to activate transcription from certain promoters. Our results obtained in the soft agar assays suggest that the recruitment of the TFIID complex is not the rate limiting step in the transcriptional activation for at least some of the FLI-1 responsive genes in vivo. Moreover, tethering RNA Pol II to FLI-1 promoters does not lead to transcriptional activation of the FLI-1 responsive genes. This result suggests that arti®cial recruitment of Pol II to FLI-1 responsive promoter is not sucient to activate transcription. A similar result has been obtained fusing ten dierent Pol III subunits to the GAL4 DBD (Marsolier et al., 1994) , suggesting that RNA polymerase recruitment is not sucient to initiate transcription. Furthermore, since the GCN5-FLI-1 chimera did not eciently activate transcription or result in oncogenic transformation, it is conceivable that the recruitment of a histone acetylase activity is not sucient to overcome the physical need for an activation domain. To date, the only HAT which is able to activate transcription from a promoterproximal position, when fused to a DBD, is the CBP/p300 HAT which may have the ability to interact with TFIID and the RNA polymerase II holoenzyme simultaneously (Abraham et al., 1993; Nakajima et al., 1997) .
Nevertheless, since the arti®cial recruitment of HAT-, TFIID-or Pol II-FLI-1 chimeras did not bypass the physical need for TAF II 68 and EWS activation domains on ETS-responsive promoters we would rather speculate that the FLI-1 responsive genes are activated by TAF II 68-FLI-1 or EWS-FLI-1 at a post-recruitment step. In vivo at certain promoters of transcriptionally inactive genes the PIC can be found prebound but inactive (Chen et al., 1994; Barberis and Gaudreau, 1998) and therefore transcription cannot be activated by the additional recruitment of components of the PIC. In agreement with our study, others have shown that certain promoters such as the human immunode®ciency virus 1 (HIV-1) LTR cannot be activated by arti®cial recruitment (Xiao et al., 1997) . The fact that the TFIID-, Pol II-or GCN5-FLI-1 fusions have an inhibitory eect on transcription (see Figure  5 ), show that these fusions can bind to their binding sites and suggest that they are unable to in¯uence a step after PIC formation in NIH3T3. Consequently, GAL-TBP induces mainly short transcripts in the absence of TAT from the HIV LTR, containing a GAL4 binding site (Majello et al., 1998) , suggesting that GAL-TBP can enhance recruitment of the PIC, but in contrast to other activators it is unable to aect the processivity of Pol II. Certain transcriptional activators (i.e. VP16 or HSF) have been shown to act at events after PIC formation, at steps like promoter clearance or stimulation of elongation (Blair et al., 1996; Blau et al., 1996; Yankulov et al., 1994; Lis and Wu, 1993) . Our preliminary results indicating that TAF II 68 is able to activate transcription elongation in vitro (A Bertolotti and L Tora unpublished results) strongly suggest that the TAF II 68 or EWS activation domains play an important role after PIC formation. This interpretation is consistent with the fact that the activation domain of VP16, which stimulates elongation, when fused to FLI-1 is able to induce oncogenic transformation in NIH3T3 cells , similarly to TAF II 68 and EWS. Thus, in order to activate transcription eciently TAF II 68-FLI-1 and EWS-FLI-1 may stimulate the transcription elongation process in vivo and may belong in a class of activators which can enhance both initiation and elongation.
In conclusion, we have demonstrated here that the N-terminal domain of hTAF II 68 has transcriptional and transforming activities. The present data are the ®rst to directly show that genes encoding TFIID subunits can be proto-oncogenes. Taken together with our previous work showing that the other TET family members, TLS and EWS, can enter TFIID complexes (Bertolotti et al., 1996 (Bertolotti et al., , 1998 , our data strengthen the link between oncogenic transformation by derivatives of TET family members and the deregulation of Pol II transcription. Moreover, our investigation into the mechanism of transformation by TAF II 68-FLI-1 and EWS-FLI-1 suggest that neither the recruitment of TAF II 68 and EWS targets TFIID or Pol II subunits, nor the recruitment of a HAT activity can recapitulate the transactivation and/or transforming functions of the N-termini of TAF II 68 and EWS. These results are consistent with recent data suggesting that a bona ®de transcriptional activation domain performs functions in addition to the recruitment of individual components of the PIC (He and Weintraub, 1998; Nevado et al., 1999) .
Materials and methods
Construction of GAL4 and FLI-1 fusion proteins cDNAs encoding EWS and hTAF II 68 were PCR ampli®ed with the appropriate restrictions sites, digested and inserted in frame with the GAL4 (1 ± 147) DNA binding domain into the pG4M polyII vector (Webster et al., 1988a) (Figure 1a) . The FLI-1 cDNA in the pCMV Neo expression vector was described in (Petermann et al., 1998) . The cDNA encoding FLI-1 was PCR ampli®ed with SnaBI and SalI sites and inserted in the corresponding sites of the pBabe Puro vector (Morgenstern and Land, 1990) . The EWS-FLI-1, TAF II 68-FLI-1 and TBP-FLI-1 fusions were generated by PCR with the appropriate restriction sites. EWS-FLI-1¯anked by SnaBI and SalI sites was inserted in the corresponding sites of the of the pBabe Puro (Morgenstern and Land, 1990) and in the SmaI and XhoI sites of the pXJ41 (Xiao et al., 1991) . TAF II 68-FLI-1 and TBP-FLI-1¯anked by BamHI and SalI sites were inserted into the corresponding sites of the pBabe Puro vector and in BamHI and XhoI sites of the pXJ41 (Xiao et al., 1991) .
To generate the TAF II 28-FLI-1, RPB3-FLI-1, RPB7-FLI-1 and GCN5-FLI-1 the cDNA encoding the C-terminal 233 amino acids FLI-1 was ®rst PCR ampli®ed with HindIII and SalI sites and inserted into the corresponding sites of the BSK+ vector (PharMingene). The cDNA corresponding to hTAF II 28 (Mengus et al., 1995) , hRPB3 and hRPB7 (Acker et al., 1997) or hGCN5-S (Candau et al., 1996) were PCR ampli®ed (see Figure 1 ) with BamHI and HindIII sites and inserted in frame into the same sites of the BSK-FLI-1 plasmid described above. Then the dierent cDNAs encoding the various FLI-1 fusion proteins were excised from the pBSK+ using a BamHI-SalI digestion. The inserts were then recloned into the BamHI and SalI sites of the pBabe Puro vector and into the BamHI and XhoI sites of the pXJ41 vector (Xiao et al., 1991) . All constructs were veri®ed by sequencing.
Transfections and CAT assays
HeLa cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 5% fetal calf serum. Approximately 10 6 cells were seeded and transfected 1 h after by the calcium phosphate co-precipitation method. In addition to the expression vectors or reporter plasmids described in each ®gure, all transfections contain 1 mg of the luciferase reporter pRSV-Luc (de Wet et al., 1987) as an internal standard and pBSK-as a DNA carrier up to 20 mg. Cells were incubated with the DNA coprecipitate for 12 h, washed, further grown and harvested 40 h after transfection. Luciferase assays were performed as described in (de Wet et al., 1987) and quanti®ed using a Berthold MicroLumat luminometer. CAT assays were performed by standard procedure (Sambrook et al., 1989) using amount of protein extracts normalized to the luciferase activity. Quantitative phosphoimager analysis was performed on a Fujix BAS 2000 apparatus. Similar results (+5%) were obtained in at least three independent transfections. The results of typical experiments are shown in the ®gures. Fold stimulation by the dierent activators is measured with respect to the reporter gene cotransfected with the empty expression vector.
Nuclear extract, Western blot and antibodies
Nuclear extract was performed as described in (Bertolotti et al., 1998) modi®ed for small scale preparation. Approximately 2610 7 cells were washed with PBS, collected and resuspend in 200 ml buer I [50 mM Tris-HCl pH 7.9, 1 mM EDTA, 1 mM DTT], containing 2.5 mg/ml of leupeptin, pepstatin, aprotinin, antipain, and chymostatin and gently vortexed for 10 min on ice. Cell lysates were centrifuged 5 min at 3000 g and nuclear pellets were resuspended in 150 ml buer II [50 mM Tris-HCl pH 7.9, 25% (v/v) glycerol, 0.5 M Nacl, 1 mM EDTA, 1 mM DTT], containing 2.5 mg/ml of leupeptin, pepstatin, aprotinin, antipain, and chymostatin. Cell nuclei were broken by ten passages through a 27G needle, followed by three cycles of freeze-thaw. Insoluble material was removed by a 10 min centrifugation at 13000 g and the supernatant (nuclear extract) was collected. Western blots were performed exactly as described in (Bertolotti et al., 1998) . The chimeric FLI-1 fusion proteins were detected by Western blots using the mAb7.3 described in (Melot et al., 1997) .
Transformation assay
Replication de®cient retroviral stocks were created as described in (Pear et al., 1993) . Brie¯y, BOSC 23 packaging cells were transiently transfected (Pear et al., 1993) with FLI-1 or the various fusions described above cloned in the pBabe Puro vector. Medium containing the dierent viruses was harvested and used to infect NIH3T3 cells. Following infection, cells were cultured 5 days under selection with puromycin (2,5 mg/ml). The transduction eciency was approximately the same for each construct (more than 90%). Nuclear extract were prepared from these polyclonal selected cell populations and analysed by Western blot to control the level of expression of the dierent FLI-1-fusion proteins. Soft agar assays were performed as follows. 8610 3 cells were seeded per 3 cm diameter plate in 1.5 ml DMEM containing 10% calf serum (CS) and 0.3% noble agar (Difco) on a 3 ml layer of 0.6% noble agar in the same media. The following day, a top layer of 0.3% agar was added and the culture were fed with DMEM containing 10% CS every 4 days. Macroscopically visible colonies were observed after 1 week of growth and scored after 3 weeks. Plates were photographed at a 3.56 magni®cation after 3 weeks of growth. Each experiment was performed in duplicate at least three times and the result of a typical experiment is presented in the ®gures.
Note added in proof
While this manuscript has been processed for publication SjoÏ rgen et al. [Cancer Research, 59, 5054 ± 5067, (1999) ] identi®ed the gene encoding hTAF II 68 (TAF2N) as a fusion partner to the TEC1 gene (see Introduction) in extraskeletal myxoid chodrosarcomas. In these sarcomas the chromosomal translocation created an oncoprotein in which the ®rst 159 amino acids of TAF II 68 (the same domain fused to FLI-1 in our study) are fused in frame to the entire TEC1 protein. Thus, the TAF II 68 is a protooncogene.
